Skip to content

Author

R. Reshef

We have 4 of 381 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Spatiotemporal single-cell profiling reveals T cell clonal dynamics and phenotypic plasticity in human graft-versus-host disease

Allogeneic hematopoietic cell transplantation cures hematologic diseases but is limited by acute graft‑versus‑host disease. How human T cell clones drive epithelial injury remains poorly mapped. We studied 31 transplant recipients, integrating longitudinal T cell antigen receptor (TCR) profiling with single-cell RNA se...

Ling-Ting Shi, Ajna Uzuni, X. Wang et al. · 0 citations
Open access Aug 2026

Outcomes after 7/8 and <7/8 mismatched unrelated donor PBSC transplantation with PTCy: results from the ACCESS trial.

Among adult ACCESS recipients treated on a uniform young-donor PBSC/PTCy platform, short-term outcomes with predominantly 6/8 MMUD transplantation were encouraging and should not be interpreted as establishing equivalence with 7/8 MMUD transplantation.

A. J. Jimenez Jimenez, Joseph Stanek, Brent Logan et al. · 0 citations
Open access Aug 2026

Phase II Study of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After HLA-Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort.

MMUD with PTCy-based GVHD prophylaxis and RIC/NMA conditioning was safe and effective to facilitate HCT and outcomes were similar in the expansion cohort that enrolled from a greater number of centers.

Brian C. Shaffer, M. A. Al Malki, Antonio M. Jimenez et al. · 0 citations
Open access Aug 2026

Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes.

A multicenter, retrospective study of patients with LBCL assessed in real time with a commercially available, immunoglobulin rearrangement-targeted ctDNA-MRD assay (clonoSEQM), finding post-treatment MRD after immunochemotherapy or chimeric antigen receptor T-cell (CAR-T) therapy was 15% versus 85% for detectable versu...

Patrick Gould, D. Coskey, Xin Ma et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.